1002106-09-3

Basic information

• Product Name: methyl 6-chloro-2-fluoro-3-formylbenzoate
• Synonyms: methyl 6-chloro-2-fluoro-3-formylbenzoate
• CAS NO: 1002106-09-3
• Molecular Weight: 216.596
• Mol File: 1002106-09-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 6-chloro-2-fluoro-3-formylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 6-chloro-2-fluoro-3-formylbenzoate(1002106-09-3)
• EPA Substance Registry System: methyl 6-chloro-2-fluoro-3-formylbenzoate(1002106-09-3)

Safety Data

• Hazardous Substances Data: 1002106-09-3(Hazardous Substances Data)

Usage

General Description

Methyl 6-chloro-2-fluoro-3-formylbenzoate is a chemical compound with a molecular formula C9H6ClFO3. It is a fluoroformylbenzoate derivative with a chlorine atom and a fluorine atom substituted on the benzene ring. methyl 6-chloro-2-fluoro-3-formylbenzoate is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and organic compounds. It is known for its potent and diverse biological activities, making it a valuable building block in the development of new drugs and active ingredients. Additionally, it has also shown potential as a key ingredient in the production of pesticide and insecticide formulations.

Upstream product

• 151360-57-5 methyl 2-chloro-6-fluorobenzoate 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1011804-87-7 methyl 6-chloro-2-fluoro-3-(N'-hydroxy-N-(3-(trifluoromethyl)phenyl)carbamimidoyl)benzoate 
• 1011804-89-9 methyl 6-chloro-3-(3-(trifluoromethyl)phenylamino)benzo[d]isoxazole-7-carboxylate 
• 1002106-11-7 methyl-6-chloro-3-(chloro(hydroxyimino)methyl)-2-fluorobenzoate 

Relevant articles and documents

Discovery of amido-benzisoxazoles as potent c-Kit inhibitors

Deregulation of the receptor tyrosine kinase c-Kit is associated with an increasing number of human diseases, including certain cancers and mast cell diseases. Interference of c-Kit signaling with multi-kinase inhibitors has been shown clinically to successfully treat gastrointestinal stromal tumors and mastocytosis. Targeted therapy of c-Kit activity may provide therapeutic advantages against off-target effects for non-oncology applications. A new structural class of c-Kit inhibitors is described, including in vitro c-Kit potency, kinase selectivity, and the observed binding mode.

DI-AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating the c-kit receptor and, accordingly, useful for treatment of c-kit mediated diseases, including various fibrotic and mast cell related diseases such as mastocytosis. The compounds have a general Formula I wherein R1-6, X and Y are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.